"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
Descriptor ID |
D007004
|
MeSH Number(s) |
D27.505.696.422
|
Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 1 | 2 |
1996 | 1 | 0 | 1 |
1997 | 3 | 4 | 7 |
1998 | 2 | 3 | 5 |
1999 | 0 | 2 | 2 |
2000 | 4 | 3 | 7 |
2001 | 1 | 3 | 4 |
2002 | 4 | 2 | 6 |
2003 | 4 | 2 | 6 |
2004 | 4 | 2 | 6 |
2005 | 5 | 3 | 8 |
2006 | 7 | 4 | 11 |
2007 | 4 | 4 | 8 |
2008 | 5 | 3 | 8 |
2009 | 4 | 6 | 10 |
2010 | 3 | 5 | 8 |
2011 | 4 | 5 | 9 |
2012 | 3 | 3 | 6 |
2013 | 8 | 7 | 15 |
2014 | 13 | 8 | 21 |
2015 | 14 | 6 | 20 |
2016 | 10 | 7 | 17 |
2017 | 11 | 6 | 17 |
2018 | 5 | 10 | 15 |
2019 | 9 | 11 | 20 |
2020 | 2 | 7 | 9 |
2021 | 1 | 12 | 13 |
2022 | 2 | 5 | 7 |
2023 | 1 | 7 | 8 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Individualizing Care for Older Adults With Diabetes Amid the Revolution in Pharmacotherapy. JAMA Intern Med. 2024 Apr 01; 184(4):435-436.
-
Metformin Use and Age-Related Macular Degeneration in Patients Without Diabetes. JAMA Ophthalmol. 2024 Jan 01; 142(1):53-57.
-
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial. Lancet Diabetes Endocrinol. 2023 Dec; 11(12):892-894.
-
Multivariable Automated Insulin Delivery System for Handling Planned and Spontaneous Physical Activities. J Diabetes Sci Technol. 2023 11; 17(6):1456-1469.
-
5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine. Diabetes Obes Metab. 2024 Feb; 26(2):463-472.
-
Type 2 Diabetes - Controlling the Epidemic, Episode 4: Understanding Old and New Therapies for Diabetes. N Engl J Med. 2023 Oct 19; 389(16):e31.
-
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 08 31; 38(9):2041-2051.
-
Glycemic control and diabetes complications across health status categories in older adults treated with insulin or insulin secretagogues: The Diabetes & Aging Study. J Am Geriatr Soc. 2023 12; 71(12):3692-3700.
-
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. J Am Coll Cardiol. 2023 06 27; 81(25):2377-2387.
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Ann Intern Med. 2023 04; 176(4):eL230007.